This is a non-core endpoint: only basic statistics are computed.
Benign neoplasm of soft tissue of retroperitoneum and peritoneum (controls excluding all cancers)
CD2_BENIGN_RETROPERITONEUM_PERITONEUM_EXALLC
No definition available.
Endpoint definition
↥
FinnGen phenotype data
individuals
Apply sex-specific rule None
Check conditions None
Check pre-conditions, main-only, mode, registry filters
Hospital Discharge: ICD-10
D20
Hospital discharge: ICD-9
2118
Hospital discharge: ICD-8
2117
Cause of death: ICD-10
D20
Cause of death: ICD-9
2118
Cause of death: ICD-8
2117
2 out of 7 registries used, show all original rules.
-
Check minimum number of events None
-
Include endpoints None
-
Remove individuals based on genotype QC
154
CD2_BENIGN_RETROPERITONEUM_PERITONEUM_EXALLC
Control definitions
Control exclude
C3_CANCER
Extra metadata
Level in the ICD hierarchy
2
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
D10-D36
Name in latin
Neoplasma benignum telae mollis spatii retroperitonealis et/sive peritonei
No upset plot: script not run.
No upset table: script not run.
Similar endpoints
↥List of similar endpoints to
Benign neoplasm of soft tissue of retroperitoneum and peritoneum (controls excluding all cancers)
based on the number of shared cases.
Broader endpoints:
- Benign neoplasm of soft tissue of retroperitoneum and peritoneum
- Benign neoplasms
- Benign neoplasms (controls excluding all cancers)
- Neoplasms
- Any operation in hilmo
Narrower endpoints:
Summary Statistics
↥Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 154 | 108 | 46 |
| Unadjusted prevalence (%) | 0.04 | 0.05 | 0.03 |
| Mean age at first event (years) | 53.55 | 51.43 | 58.54 |
Mortality
Not a core endpoint, no data to show.
Age distribution of first events
Year distribution of first events
Cumulative Incidence
Not a core endpoint, no data to show.
Correlations
↥
Index endpoint: CD2_BENIGN_RETROPERITONEUM_PERITONEUM_EXALLC – Benign neoplasm of soft tissue of retroperitoneum and peritoneum (controls excluding all cancers)
GWS hits:
Survival analyses between endpoints
↥Not a core endpoint, no data to show.
Drugs most likely to be purchased after Benign neoplasm of soft tissue of retroperitoneum and peritoneum (controls excluding all cancers)
↥Endpoint not on priority list, no data to show.